Coloplast Estimates Broadly Unchanged

Goldman Sachs reiterates its Sell rating on Coloplast with a DKK 400 price target after H1 26 earnings, slightly reducing EPS estimates due to FX while noting a major DKK 3bn impairment for Kerecis.

Key Takeaways

• 1.Goldman Sachs maintains its Sell rating on Coloplast with a 12-month price target of DKK 400.
• 2.EPS estimates for FY26-28e were lowered by less than 0.5%, primarily driven by FX headwinds rather than fundamental changes.
• 3.Reported EPS for FY26 is expected to fall by approximately 45% due to a one-time DKK 3bn impairment charge related to Kerecis.

Table of Contents

• Changes to estimates
• Our PT remains unchanged at DKK 400.
• Disclosure Appendix
• GS Factor Profile
• M&A Rank
• Quantum
• Disclosures
• Company-specific regulatory disclosures
• Price target and rating history chart(s)
• Target price history table(s)
• Regulatory disclosures
• Global product; distributing entities
• General disclosures
• Ratings, coverage universe and related definitions

Document Preview

Page 1 of 5

Subscribe for full accessStart Free Trial